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Abstract
In HIV infection, TLR7-triggered IFN-a production exerts a direct antiviral effect through the inhibition of viral replication,
but may also be involved in immune pathogenesis leading to AIDS. TLR7 could also be an important mediator of vaccine
efficacy. In this study, we analyzed polymorphisms in the X-linked TLR7 gene in the rhesus macaque model of AIDS. Upon
resequencing of the TLR7 gene in 36 rhesus macaques of Indian origin, 12 polymorphic sites were detected. Next, we
identified three tightly linked single nucleotide polymorphisms (SNP) as being associated with survival time. Genotyping of
119 untreated, simian immunodeficiency virus (SIV)-infected male rhesus macaques, including an ‘MHC adjusted’ subset,
revealed that the three TLR7 SNPs are also significantly associated with set-point viral load. Surprisingly, this effect was not
observed in 72 immunized SIV-infected male monkeys. We hypothesize (i) that SNP c.13G.A in the leader peptide is
causative for the observed genotype-phenotype association and that (ii) the underlying mechanism is related to RNA
secondary structure formation. Therefore, we investigated a fourth SNP (c.-17C.T), located 17 bp upstream of the ATG
translation initiation codon, that is also potentially capable of influencing RNA structure. In c.13A carriers, neither set-point
viral load nor survival time were related to the c.-17C.T genotype. In c.13G carriers, by contrast, the c.-17C allele was
significantly associated with prolonged survival. Again, no such association was detected among immunized SIV-infected
macaques. Our results highlight the dual role of TLR7 in immunodeficiency virus infection and vaccination and imply that it
may be important to control human AIDS vaccine trials, not only for MHC genotype, but also for TLR7 genotype.
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Introduction
Toll-like receptor 7 (TLR7) localizes to intracellular vesicles in
antigen-presenting cells such as plasmacytoid dendritic cells,
macrophages, memory B cells and T cells. In these cells, TLR7
functions as a receptor for pathogen recognition in that it binds
ligands like uridine-rich single-stranded (ss) RNAs or certain small
interfering RNAs [1,2,3,4]. Through the recognition of ssRNA
derived from RNA viruses, TLR7 can also act as a danger
receptor for viral infection (reviewed in [5,6,7]). Moreover, TLR7
activation modulates the innate and adaptive antiviral immune
response by triggering the production of type I interferons,
cytokines and chemokines [8,9]. The X-linked TLR7 gene appears
to have been subject to positive selection during primate evolution,
thereby underpinning its relevance in host-pathogen interaction
[10].
TLR7 activation is an important mediator of vaccine efficacy.
Targeting of TLR7 by synthetic agonists like polyUs21, or
conjugation of TLR7 to a protein vaccine, can prime high-
frequency polyfunctional type 1 T helper cell (Th1) and cytotoxic
T-lymphocyte (CTL) response, probably through the activation of
plasmacytoid dendritic cells (PDC) [11,12,13]. The stimulation of
Toll-like receptors, in particular TLR7, also appears to be a
determinant of the greater magnitude and Th1 polarization of the
immune response induced by inactivated whole-virus H5N1
influenza vaccine, as compared to split or subunit vaccine-induced
responses [14]. Furthermore, IGA responses important for
mucosal immunity potentially also depend upon TLR7 activation
[15]. Targeting TLR7 may therefore improve vaccine efficacy.
In HIV infection, TLR7-triggered IFN-a production appears to
be a double-edged sword [16]. On the one hand, stimulation of
antigen-presenting cells by synthetic TLR7 agonists like imidazo-
quinoline compounds augment HIV-1-specific T cell responses in
vitro [17]. Moreover, administration of IFN-a or triggering of
TLR7/8 by imidazoquinoline compound R848 has direct anti-
HIV effects by inhibiting viral replication in vitro, and potentially in
vivo, through multiple pathways [18,19,20,21,22,23]. On the other
hand, TLR7-triggered pathways appear to be directly involved in
immune pathogenesis leading to AIDS [24,25]. Chronic immune
stimulation via TLR7 in mice caused progressive lymphoid system
destruction resembling HIV-mediated immunopathology [26].
Opposing effects of TLR7 have also been observed in the context
of respiratory syncytial virus infection (RSV) in mice. Whereas
administering TLR7/8 agonists during immunization did hardly
influence the phenotype upon challenge with RSV, the immunos-
timulatory properties of the same agonists increased disease
severity when used in mice that had already been infected [27].
Finally, since IFN-a production is particularly enhanced in females
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specific disease progression [24,28].
The pathophysiological role of TLR7 can be studied in some
detail in humans owing to a functional polymorphism located in
the signal peptide. This Q11L amino acid replacement (rs179008)
has been shown to confer susceptibility to asthma [29] and to
influence the course of hepatitis C infection [30], HIV disease
progression and potentially HIV-1 acquisition [31]. Peripheral
blood mononuclear cells (PBMCs) from individuals carrying the
minor allele (11L) secreted less IFN-a upon stimulation by TLR7
agonist Imiquimod compared to PBMCs from individuals carrying
the major allele [31]. Interestingly, the allele associated with
diminished ex vivo IFN-a secretion was also associated with an
accelerated time to onset of antiviral therapy (CD4 counts.
350 ml) and higher set-point viral load in HIV-infected patients
[31], indicating that the protective antiviral effects of TLR7 may
prevail in the initial and chronic phases of infection.
The important role of TLR7 in viral infection and immuniza-
tion prompted us to characterize TLR7 gene polymorphisms in
simian immunodeficiency virus (SIV)-infected rhesus macaques
(Macaca mulatta), which represent the most important animal model
of HIV infection. Moreover, the expression patterns of TLR7 and
other TLRs in antigen-presenting cells such as dendritic cells,
monocytes and B cells are similar in macaques and humans, but
differ markedly from the expression profiles in mice [32]. TLRs
also respond to the same ligands in macaques as in humans [32].
Upon targeted TLR7 re-sequencing in 36 rhesus macaques of
Indian origin, we detected 12 polymorphisms and subsequently
investigated their possible association with AIDS-free survival and
viremia in SIV-infected animals. We identified two polymor-
phisms, located immediately upstream and downstream of the
TLR7 translation initiation codon, to be associated with survival
time and/or set-point viral load in untreated SIV-infected macaques.
Interestingly, no such association was evident in immunized-
infected macaques.
Results
Variability of the rhesus TLR7 gene
Like in humans and many other species, the X-linked TLR7
gene in rhesus macaque contains three exons, namely two
untranslated exons encompassing the 59 untranslated region
(59UTR) and the ATG translation initiation codon, and exon 3
spanning the sequence coding for the leader peptide, the mature
TLR7 polypeptide and a 39 untranslated region (39UTR) of about
1700 bp not yet annotated firmly in rhesus macaque. In contrast
to the human situation, however, no polymorphisms in the rhesus
TLR7 gene were known prior to this study. We therefore had to
establish a panel of polymorphisms first before we could assess the
impact of TLR7 gene variability upon the progression and
outcome of SIV infection in this species.
Initial DNA sequence analysis of all three exons and some
intronic parts of the TLR7 coding region, comprising a total of
7853 bp, was performed in a pilot sample 36 animals. Twelve
variable positions were identified in the DNA sequence encoding
the TLR7 mRNA (Figure S1), four of which were located in the
protein-coding region of TLR7 (Figure S2). Two of the coding
polymorphisms were non-synonymous whilst two were synony-
mous. The rhesus TLR7 amino acid sequence differs from human
TLR7 by 19 amino acid substitutions (Figure S2). Notably, the
amino acid sequences encoding the transmembrane and the Toll/
IL-1 receptor (TIR) domain important for transport and
associated signalling are identical in humans and rhesus macaques,
and no polymorphisms were detected in these regions (Figure S2).
Seven of the eight non-coding polymorphisms were located in the
39UTR of exon 3 whereas one was found in exon 2, 17 bp
upstream of the ATG translation initiation codon. Since the rhesus
genome is not yet annotated as thoroughly as the human genome,
we provisionally labelled the SNPs following the recommendations
for the description of DNA sequence variants made by the Human
Genome Variation Society [33]. Allele frequencies observed
among the 36 macaques of the pilot sample are given in Table 1.
Four single nucleotide polymorphisms (SNPs) were also geno-
typed in a larger sample. Thus, a total of 237 animals of Indian
origin (46 females, 191 males), including the 36 samples used in the
re-sequencing experiment, were investigated for SNPs c.-17C.T
(59UTR), c.13G.A (V5M), c.1710T.A (V570V) and c.*1604C.
T( 3 9UTR). The last three polymorphisms were in strong pair-wise
linkage disequilibrium (LD) in our sample (all pair-wise allelic
r
2.0.90) so that the respective allele frequencies were very similar
(Table 1). Allele frequencies also differed hardly between the initial
re-sequencing panel and the larger validation sample (data not
shown).
Association of TLR7 polymorphisms c.13G.A, c.1710T.A
and c.*1604C.T with survival time and viral load in
untreated SIV-infected rhesus macaques
The initial re-sequencing experiment was carried out on 36
unrelated SIV-infected rhesus macaques that displayed the whole
spectrum of disease progression (i.e., AIDS-free survival from 6 to
.580 weeks post infection). Three of the discovered SNPs, namely
c.13G.A, c.1710T.A, and c.*1604C.T, were suggestive of an
association with survival time in the pilot sample. For further
validation, a larger sample of 237 SIV-infected macaques was
genotyped for the three SNPs either by Sanger sequencing or
using a TaqMan-based allelic discrimination assay. In the
following, we will only report upon c.13G.A, because the other
two SNPs were in strong LD with this polymorphism (see above).
Among the 119 untreated-infected male macaques genotyped,
AIDS-free survival was found to be significantly associated with
the c.13G.A hemizygous status. Thus, male macaques carrying
the minor allele (c.13A) progressed faster to AIDS than macaques
carrying the major allele (c.13G; log-rank x
2=5.04, 1 d.f,
p=0.025) (Fig. 1A). Furthermore, c.13A carriers had a signifi-
cantly higher viral load at set-point (F=6.82, p=0.011) (Fig. 2A).
Table 1. Major allele frequencies (MAF) of 12 TLR7 gene
polymorphisms in 36 rhesus macaques of Indian origin.
Polymorphism Genomic Position MAF
c.-17 C.T 1056561 0.74
c.13 G.A (V5M) 10583408 0.68
c.204 A.G (T68A) 10583597 0.56
c.1710 T.A (V570V) 10585105 0.69
c.2352 G.A (R784R) 10585747 0.52
c.*437 G.A 10586982 0.94
c.*236 A.G 10587281 0.50
c.*867 T.C 10587412 0.82
c.*908_1911delGGCT 10587453 0.94
c.*941 A.G 10587483 0.81
c.*1604 C.T 10588146 0.69
c.*1681 A.G 10588222 0.85
doi:10.1371/journal.pone.0025474.t001
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observed, indicating that initial viral replication is not strongly
influenced by c.13G.A genotype (F=1.33, p=0.252).
Since the MHC genotype is known to influence both survival
time and viral load in HIV-infected humans as well as in SIV-
infected macaques, we controlled our analysis for the presence for
MHC genotypes known to strongly influence disease progression
(Figure S3). Inspection of the data revealed that MHC genotypes
previously found to be associated with either rapid or slow disease
progression were not evenly distributed among the male animals
studied here [34]. In the group of c.13A carriers, MHC-genotypes
associated with rapid disease progression were significantly
overrepresented compared to c.13G carriers (17.1% vs. 2.4%;
Fisher’s exact test p=0.008) whereas MHC genotypes associated
with slow disease progression (Mamu-A1*001, -B*008) were
underrepresented (8.3% vs. 20.2%), although the second differ-
ence failed to reach statistical significance (Fisher’s exact test,
p=0.389). After excluding all of these animals from the analysis
(‘MHC adjustment’), survival times were no longer significantly
different between the two c.13G.A genotypes (log-rank x
2=4.14,
1 d.f., p=0.077) but still showed a trend towards longer survival
being associated with c.13G (Fig. 1B). However, even in the
smaller, MHC-adjusted sample comprising 63 monkeys, c.13A
carriers still had a significantly higher set-point viral load than
c.13G carriers (F=6.02, p=0.017) whilst peak viral load did not
differ between genotypes (F=0.61, p=0.439).
Figure 1. Kaplan-Meier curves of AIDS free survival of SIV-infected male rhesus macaques carrying allele c.13A (blue line) or c.13G
(red line) of TLR7 SNP c.13G.A. A: untreated-infected macaques (c.13A: n=35, c.13G: n=84) (p=0.025); B: untreated-infected macaques after
MHC adjustment (c.13A: n=26, c.13G: n=69) (p=0.077); C: untreated-infected macaques after MHC adjustment carrying haplotype c.-17T,c.13A (blue
discontinuous line, n=14), c.-17C,c.13A (straight blue line, n=11), c.-17T,c.13G (red discontinuous line, n=18), c.-17C,c.13G (straight red line, n=51);
(c.13G carriers: c.-17C.T: p=0.017); D: immunized-infected macaques carrying c.-17C,c.13A , c.-17T,c.13A or c.-17T,c.13G (blue line, n=38) or
c.-17C,c.13G (red line, n=34) (p.0.3).
doi:10.1371/journal.pone.0025474.g001
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available to seek evidence for a potential sex difference in terms
of the observed genotype-phenotype relationship. Whilst only one
female was homozygous for -c.13A, c.AG heterozyotes and c.GG
homozygotes were almost equally frequent (13 vs. 14). The
relevant MHC genotypes were evenly distributed between both
groups and no significant difference in AIDS-free survival time
was apparent between AG and GG females (log-rank x
2=0.155, 1
d.f., p=0.694). Further analyses were not deemed meaningful in
view of the small sample size.
TLR7 polymorphism at position 217 (c.-17C.T)
influences set-point viral load and survival time in c.13G
carriers
Polymorphisms close to the ATG start codon can affect
translation initiation and thus the protein expression. We therefore
Figure 2. Plasma RNA copy number at peak (2 wpi) and set-point (20 wpi) of SIV-infected male rhesus macaques, stratified by the
TLR7 genotype. Geometric mean and 95% confidence interval are indicated by error bars. Significant differences are marked by asterisks. A:
untreated SIV-infected carriers of allele c.13A (n=23) or c.13G (n=54), and untreated SIV-infected monkeys after MHC adjustment carrying c.13A
(n=17) or c.13G (n=46). B: untreated SIV-infected rhesus macaques stratified by their joint c.-17C.T and c.13G.A genotype: c.-17C,c.13A (n=12),
c.-17T,c.13A (n=10), c.-17T,c.13G (n=12), c.-17C,c.13G (n=34). C: plasma RNA copy numbers of immunized SIV-infected macaques carrying c.13A or
c.-17T,c.13G (n=33), c.-17C,c.13G (n=31), MHC adjusted: c.13A or c.-17T,c.13G (n=20), c.-17C,c.13G (n=18), carrying MHC alleles associated with slow
disease progression: c.13A or c.-17T,c.13G (n=11) , c.-17C,c.13G (n=10).
doi:10.1371/journal.pone.0025474.g002
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located in exon 2, which is not in linkage disequilibrium with the
polymorphisms in exon 3. Exon 2 of the TLR7 gene is remarkably
conserved between human and rhesus macaque, and no
polymorphisms have been detected in the respective human
sequence so far. Since the polymorphisms at position 217 and +13
might both alter the local RNA secondary structure, we analyzed
the phenotypic effect of the 217 polymorphism separately in both,
c.13A and c.13G males. Among the 34 c.13A carriers, the c.-
17C.T status was not significantly associated with either survival
time, set-point viral load (both p.0.5) or peak viremia (p.0.1).
From this analysis, only a single long-term non-progressing
monkey carrying Mamu-A1*001 and -B*017 was excluded because
all other MHC genotypes were almost identically distributed within
the two c.13G.A genotype-defined groups (Figures 1C, 2B). Note,
however, that only MHC adjusted monkeys are shown in
Figures 1C and 2B in order to allow direct comparison with
Figures 1B and 2A. MHC adjustment reduced the number of
monkeys analysed but did not change the results of the statistical
analysis.
In c.13G carriers, by contrast, the c.-17C.T polymorphism was
significantly associated with survival time (log-rank x
2=5.66, 1
d.f., p=0.017), but not with set-point or peak viral load (both
p.0.5). Only MHC adjusted monkeys were included in this
analysis because of the overrepresentation of slow progressor
genotypes among c.-17C,c.13G carriers. Interestingly, survival time
(p.0.6) and set-point viral load (p.0.1) did not differ significantly
between c.13A and c.-17T,c.13G carriers, but between c.13A and
c.-17C,c.13G carriers (survival time: log-rank x
2=6.21, 1 d.f.,
p=0.013; set-point viral load: F=8.10, p=0.006). Thus, the
inclusion of c.-17C.T genotype was capable of refining the
genotype-phenotype association of c.13G.A. Eventually, only the
c.-17C,c.13G haplotype turned to be significantly associated with
prolonged survival and low set-point viral, compared to the other
haplotypes (see Figures 1C, 2D).
No association of TLR7 polymorphisms with survival time
and viral load in immunized SIV-infected macaques
Next, we analyzed the influence of the TLR7 SNPs upon AIDS-
free survival and viral load in 72 immunized-infected male
monkeys. These animals were analyzed separately because their
survival time was significantly prolonged and their set-point viral
load significantly reduced compared to untreated-infected ma-
caques (both p,0.001). This difference remained significant even
after MHC adjustment (data not shown). The macaques were
immunized with different vaccine formulations, but the majority of
the respective vaccination trials included adenovirus-based vectors
[35,36,37,38]. In all experiments, peak viremia was lower among
immunized than among untreated-infected macaques. Reduced
peak viremia has been found to be associated with prolonged
survival and reduced set-point viral load before, probably
reflecting the preservation of central memory CD4
+ T cells
[35,39].
Owing to the relatively small number of immunized male
monkeys available in this study, we did not initially perform any
MHC adjustment although rapid progressors, as predicted by their
MHC genotype, were underrepresented among c.13G carriers
(2.3%) compared to c.13A carriers (11%). In the immunized-
infected macaques, neither AIDS-free survival (log-rank x
2=0.33,
1 d.f., p=0.564), nor set-point viral load (F=0.23, p=0.636) nor
peak viremia (F=0.32, p=0.574) were found to be significantly
associated with c.13G.A genotype. Subsequent MHC adjustment
led to insignificant results as well (all p.0.3). Immunized
macaques carrying TLR7 genotypes associated with more rapid
disease progression in untreated -infected animals (i.e. c.13A and
c.-17T,c.13G) did also not differ from carriers of c.-17C,c.13G (i.e.,
the haplotype associated with slow disease progression) neither in
terms of survival time nor viral load,, and even after MHC
adjustment (Figures 1D, 2C).
A trend towards prolonged survival was observed in immu-
nized-infected female macaques compared to untreated-infected
females (log-rank x
2=3.31, 1 d.f., p=0.069). However, owing to
the small sample size (n=18), a detailed statistical analysis of the
genotype-phenotype relationship was not considered warranted.
Prediction of RNA secondary structure
Since RNA secondary structure is a major determinant of
translation kinetics and efficiency, we analysed the potential effects
upon RNA secondary structure of the SNPs associated with AIDS-
free survival. Of the three tightly linked SNPs in exon 3, only
c.13G.A, but not the two other SNPs, was found to influence
RNA secondary structure (CentroidFold program) or to change
the minimum free energy by more than 22.1 kcal/mol (RNAfold,
Vienna Websuite). For the signal peptide-encoding sequence
(position 1–78), both prediction programs calculated an identical
RNA secondary structure for the major c.13G allele, with a
minimum free energy (MFE) of 213.8 kcal/mol (Fig. 3A). The
c.13A allele disrupts this structure. The CentroidFold program
predicted no strong secondary structure (MFE=0 kcal/mol) at all
for this sequence (Fig. 3B) whereas the Vienna RNA software
predicted a secondary structure with an MFE of 28.9 kcal/mol.
Despite some minor differences, both programs therefore
suggested a destabilisation of the secondary structure of TLR7
signal peptide RNA sequence by the c.13A allele. The c.-17C.T
polymorphism in exon 2 is located in a region critical for
ribosomal entry and also influences RNA secondary structure.
Both programs predict a stronger secondary structure for c.-17C
compared to c.-17T containing RNA (MFE Centroidfold: 212.7
vs. 0 kcal/mol, RNAfold: 220.2 vs. 217.6 kcal/mol). Analyzing
the effect of the c.-17C.T polymorphism in c.13A and c.13G
carriers individually revealed that the folding effects of the two
polymorphisms may be interdependent. Centroidfold predicted an
MFE of 239.7 kcal/mol for the RNA sequence spanning exons 1
and 2 and the signal peptide-encoding region in the case of the
c.-17C,c.13G haplotype whereas the structures of the other
haplotypes had an MFE between 230.0 and 229.1 kcal/mol
(Table 2). RNAfold predicted an MFE of 251.5 kcal/mol for the
c.-17C,c.13G haplotype and of 249.7 to 247.0 kcal/mol for the
other three haplotypes. Restriction of the in silico analysis to smaller
RNA strands (25 bases up- and downstream of the c.-17 and c.13
position) yielded similar results (Table 2). Here, the c.-17C,c.13G
haplotype also had the highest MFE , and the other haplotypes
had a lower but relatively similar MFE. Despite some quantitative
discrepancies, both programs therefore suggested (i) a joint effect
of positions 217 and 13 on the RNA secondary structure and (ii)
an RNA secondary structure that is most stable for the c.-
17C,c.13G haplotype.
For comparison, we also analyzed the potential RNA secondary
structure of the human TLR7 signal peptide-coding sequence.
CentroidFold predicted an RNA secondary structure with an MFE
of ‘‘0.0 kcal/mol’’ (Fig. 3C), whereas RNAfold predicted a
structure with an MFE of 210.2 kcal/mol, indicating that the
human TLR7 signal peptide-coding RNA structure is probably
more similar to that of the rhesus c.13A allele. Both programs
predicted that the Q11L (rs179008) polymorphism, which has
been reported to influence viral load and time to AIDS in humans,
does not influence the secondary structure of the human TLR7
signal peptide-coding RNA [31].
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RNA structure, of those SNPs that were not associated with
AIDS-free survival in the initial sample of 36 macaques. The two
remaining coding polymorphisms and three of the six polymor-
phisms in the 39UTR did not change the predicted RNA
secondary structure. The polymorphisms at position c.*236,
c.*867 and the insertion/deletion c.*908_1911delGGCT
changed the calculated MFE by more than 3 kcal/mol. None
of polymorphisms in the 39UTR was located close to a likely
functional element [40]. Notably the polymorphisms at position
c.*867 and c.*908_1911delGGCT flank the site of another
functional polymorphism (TLR7 39UTR SNP, rs3853839)
reported in the human TLR7 gene [41].
Discussion
Prior to this study, no polymorphisms in the TLR7 gene locus of
rhesus macaques were known. We therefore re-sequenced the
TLR7 gene in 36 rhesus macaques of Indian origin and identified
12 polymorphisms. An initial analysis of 36 monkeys revealed
three tightly linked SNPs to be associated with disease progression.
Subsequent investigation of a larger sample of SIV-infected
monkeys confirmed this initial result. The polymorphisms were
significantly associated with viral load at set-point in untreated-
SIV-infected male rhesus macaques and showed a trend towards
an association with survival time even after the exclusion of
monkeys carrying MHC alleles associated with rapid or slow
disease progression. One of the polymorphisms of interest is
located in the 39 UTR region of the TLR7 mRNA, one is a silent
nucleotide substitution located at amino acid position 570, and the
remaining variant encodes a non-synonymous amino acid
substitution (5VM) in the leader peptide. Formally, we could not
distinguish which of these tightly linked polymorphisms may be
responsible for the differential viral load. Furthermore, each of the
three types of genetic variation seen in TLR7 is known to affect
protein expression. Mutations in the 39UTR , for instance, can
influence mRNA stability [42], silent mutations may influence
translation efficiency and protein folding [43], and variations in
the signal peptide can effect the transport, localization and
synthesis of membrane-bound proteins [44,45,46].
Figure 3. RNA secondary structure. RNA secondary structure as predicted by CentroidFold [36] of rhesus c.13G (A), rhesus c.13A (B), human (C)
signal peptide-encoding sequences, corresponding to amino acid positions 1–26. Each predicted base pair is coloured according to a gradient (from
blue to red) corresponding to the base-pairing probability (from 0 to 1). The heat colour can be interpreted as a confidence measure of the predicted
base-pairing. Red arrows indicate the polymorphic positions in the respective signal peptide DNA sequence. Plain RNA secondary structures as
predicted by RNAfold [37] are shown for rhesus c.13A (D) and human (E) signal peptide-encoding sequences. Both programs predicted identical RNA
secondary structures for rhesus c.13G. The minimal free energy (MFE) of each structure is given.
doi:10.1371/journal.pone.0025474.g003
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conservative exchange in the hydrophilic N-terminal region of the
signal peptide. Using the SignalIP program [47], we found no
evidence that the polymorphism would greatly influence process-
ing of the signal peptide, although this cannot be ruled out
completely without additional experimental evidence. In contrast,
the 11L (rs179008) substitution in the human TLR7 signal peptide
is potentially capable of altering signal peptide function (see
supplement ref [44]). More convincing results were obtained in an
analysis of RNA secondary structure. The rhesus c.13A allele very
likely destabilizes an RNA secondary structure predicted for the
c.13G allele. Interestingly, a strong RNA secondary structure
comparable to the rhesus wild-type sequence was not predicted for
the human TLR7 signal peptide RNA sequence, and it is unlikely
that the Q11L (rs179008) polymorphism will affect the secondary
structure of the signal peptide-encoding RNA sequence. Further-
more, neither the silent mutation at amino acid position 570 nor
the substitution in the 39 UTR altered the potential secondary
structure of the RNA around the respective SNPs. Based upon
these predictions, the rhesus macaque c.13A allele is a functional
candidate for the observed association with higher viral load in
untreated-infected macaques [45,46]. This result encouraged us to
also investigate the influence of an adjacent polymorphism at
position 217, which may affect the same local RNA structure and
resides in a region critical for translation initiation. In silico analyses
predicted that the effect of c.-17C.T upon RNA secondary
structure was dependent upon the nucleotide present at position
13. Notably, c.-17C.T was associated with differential survival
time only in c.13G carriers. Although translation represents a
dynamic process that cannot be captured by mere sequence
analyses, the coincidence of in silico prediction and experimental
data therefore suggests that both SNPs exert a synergistic influence
upon RNA structure.
It should be noted that, in whole genome screens involving
human HIV-1-infected patients [48,49,50], the association between
human TLR7 SNPs and disease progression did not attain statistical
significance after Bonferroni correction. The validity of the
respective associations has therefore been questioned [51]. While
variationinthe MHCregionisundoubtedlythe mostimportanthost
factor for determining disease progression, however, it explains only
a fraction of the variability in HIV viremia [48,49,50,52]. The
identification of additional host gene polymorphisms contributing
weakly to the variability of viremia or time to treatment initiation
will require much larger cohorts and, because of the variability of
the virus, the exact size of meaningful cohorts of HIV-1-infected
patients may not even be known. We therefore proposed cross-
species comparisons as a valuable means to validate potential host
gene polymorphisms influencing the course of HIV-infection [53].
This report is the third one describing similar effects of co-localising
functional genetic polymorphisms in humans and rhesus macaques
even although the affected biochemical pathways may differ
between the two species [53,54]. For TLR7, the rhesus substitution
at position 13 and 217 are more likely to influence translation
efficiency whereas the human Q11L variation probably influences
transport or localization. At last, however, both variants would
affect TLR7 expression.
Most interestingly, the TLR7 polymorphisms did not influence
plasma viral set-point and survival time in immunized macaques.
One explanation for this result could be that vaccination-induced
immune reactions such as T and B cell response had a much
stronger influence upon viral replication than differential TLR7
expression.
To better define the influence of TLR7 polymorphisms on
vaccine efficacy, larger numbers of macaques treated with the
same AIDS vaccine are required. Furthermore, it is paramount to
investigate the exact contribution of the polymorphisms on TLR7
expression and cytokine secretion in vitro and in vivo, in untreated
and infected, and in immunized subjects. Our work highlights the
dual role of TLR7 in immunodeficiency virus infection and
vaccination. Assuming that the c.13A and c.-17T,c.13G variants are
associated with enhanced TLR7 expression, the data suggest that
efficient triggering of TLR7 may improve AIDS vaccine efficacy
while attenuating the action of TLR7 may decelerate disease
progression. Finally, our results imply that it may be important to
control human vaccine trials, not only for MHC genotype, but also
for TLR7 genotype.
Table 2. Minimal free energy (MFE) of RNA secondary structures.
SNP Nucleotides analyzed
1 MFE (kcal/mol) Centroidfold
2 MFE (kcal/mol) RNAfold
3
c.-17C c.-98 to c.-1
4 212.74 220.24
c.-17T c.-98 to c.-1
4 0 217.64
c.13G c.1 to c.78
5 213.8 213.8
c.13A c.1 to c.78
5 0 29.9
c.-17C,c.13A c.-139 to c.78
6 229.96 249.66
c.-17C,c.13G c.-139 to c.78
6 239.66 251.56
c.-17T,c.17A c.-139 to c.78
6 229.13 247.0
c.-17T,c.13G c.-139 to c.78
6 229.70 249.0
c.-17C,c.13A c.-47 to c.38 214.89 214.89
c.-17C,c.13G c.-47 to c.38 217.69 220.44
c.-17T,c.13A c.-47 to c.38 215.89 215.89
c.-17T,c.13G c.-47 to c.38 214.6 217.84
1Nucleotide numbering refers to the cDNA sequence.
2Reference 36.
3Reference 37.
4Corresponding to exon 2 sequence.
5Corresponding to signal peptide encoding sequence.
6Corresponding to exon 1, exon 2 and signal peptide encoding sequence.
doi:10.1371/journal.pone.0025474.t002
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Animals and laboratory parameters
We retrospectively analyzed genetic and phenotypic data from
237 SIV-infected rhesus macaques (Macaca mulatta) of Indian
origin, seronegative for STLV-1 and D-type virus. These animals
were housed and treated at the German Primate Research Centre
(‘Deutsches Primatenzentrum’, DPZ). All relevant protocols of the
DPZ comply with the German Animal Protection Act, which in
turn follows European Union guidelines on the use of non-human
primates for biomedical research. This includes a 12:12 light dark
schedule, provision of dry food supplemented with fresh fruit twice
a day and constant water access. The monkeys were kept under
permanent medical care. In cases of suffering monkeys were
humanely killed. All experiments were approved by the indepen-
dent governmental veterinary authority of Lower Saxony. Major
characteristics of the monkeys under study and the algorithm used
to define AIDS-like disease in these animals have been described
before [53]. For the majority of samples viral RNA was isolated
from frozen plasma samples following the MagAttract Virus Mini
M48 protocol (Qiagen, Hilden, Germany). Purified SIV RNA was
quantified using TaqMan-based real-time PCR on an ABI-Prism
7500 sequence detection system (Applied Biosystems) as described
[55] using gag forward (59-ACCCAGTACAACAAATAGGTGG-
TAACT-39), gag reverse primer (59-TCAATTTTACCCAGG-
CATTTAATGT-39) and a fluorescent labeled probe (59-6FAM
(6-carboxyfluorescein)-TGTCCACCTGCCATTAAGCCCGAG-
TAMRA(6-carboxytetramethylrhodamine-39). Amplified viral
RNA was expressed as SIV-RNA copies per mL plasma. Samples
from animals infected before 2004 were analyzed using another
technique [56]. Peak and set-point viremia were quantified by the
RNA viral copy number at weeks 2 and 20 post infection,
respectively. If in addition data at week 24 post infection were
available, set-point viremia was equaled to the mean copy number
at weeks 20 and 24. Note that, for some animals included in the
survival analysis, no viral load data were available. Macaques were
designated ‘untreated’ if they had not received any AIDS vaccine.
MHC-genotyping
Monkeys were genotyped for the MHC as described before and
classified as either ‘slow progressor’, ‘rapid progressor’ or ‘unspec-
ified’[34].Survivalcurvesusedasaguideforthis‘MHCadjustment’
of the subsequent statistical analyses are shown in Figure S3.
DNA sequence analysis of TLR7
Genomic DNA was isolated from peripheral blood or from
Herpes papio virus-transformed B-cell lines using the Genomic DNA
Isolation Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. The rhesus TLR7 gene was screened
for polymorphisms by genomic re-sequencing of all three exons
and parts of the flanking intron sequence in 36 monkeys
(chrX:10564627–10566043; chrX:10582811–10589400 in the
former version, rhemac2, still available at http://genome.ucsc.
edu/cgi-bin/hgGateway). The primers used for nested PCR were
designed using Primer3Plus [57] and are listed in Table S1.
Between 25 and 50 ng of genomic DNA was used to generate the
PCR template. Sequencing was performed using ABI Big Dye
chemistry and the ABI3730xl Analyzer (ABI, Foster City, Calif.,
USA). Overlapping amplicons were sequenced to ensure that no
polymorphisms in the primer binding sites were missed. Polymor-
phisms were searched for with the GAP software (version 4.11 of
the Staden package) using the implemented SNP candidate
viewer, and by visual inspection. The DNA sequences of the
re-sequenced genomic regions and the polymorphisms identified
in these regions are deposited in GenBank (accession number
JF691587).
Genotyping of TLR7
Three polymorphisms in the TLR7 gene were initially
genotyped by means of Sanger sequencing. For amplifying the
TLR7 c.13G.A substitution, we used primers TLR7-13-for (59GG-
AAAATGCTGCTTCTACCATC) and TLR7-13-rev (59ATG-
GACCAGTCTGTGAAAGGA); the silent c.1710T.A substitu-
tion was amplified with primers TLR7-1710-for (59AAGTATGGG-
CAGACCTTGGA) and TLR7-1710-rev (59CAAAAACTCCAG-
AAGGCAAGA). For typing 39 UTR polymorphism c.*1604C.T,
we used primers TLR7-1604-for (59TCAAAGATTGAAACCTG-
ACCAA) and TLR7-1604-rev (59CAAACCACCGTACTTAAC-
CTCA). PCR was performed using 150 ng genomic DNA and
included an initial denaturation step at 94uC for 5 min, followed by
30 cycles with denaturation at 94uC for 30 s, annealing at 55uC for
30 s, and elongation at 72uC. PCR products were either
precipitated with ethanol or gel-purified using standard techniques
(Qiagen, Hilden, Germany). DNA sequencing was performed using
dye terminator chemistry and ABI 3730/3700 technology. DNA
sequences were aligned using the CLUSTALW function of the
Bioedit freeware (http://www.mbio.ncsu.edu/bioedit/bioedit.html).
Alternatively genotyping was performed by means of a
TaqMan-based allelic discrimination assay (ABI7500 Real Time
PCR System). The reaction volume of 25 ml contained 12.5 ml
ImmoMix
TM (Bioline, Luckenwalde, Germany), 660 nM ROX
(Invitrogen, USA) as an internal standard, 90 nM of the respective
primers, 20–24 nM labelled probes and 30 ng DNA. All samples
were run in triplicates. PCR was performed with an initial
denaturation step at 95uC for 10 min, a pre-read step at 60uC for
1 min, followed by denaturation at 92uC for 16 s and annealing/
amplification for 1 min at the indicated temperature for 40 cycles
and a post read step for 1 min in at 60uC. Primers and probes for
detecting the c.13G.A polymorphism were: 13-forward (59AAA-
GAGAGGCAGCAAATGGGA), 13-reverse (59AACCATCTAG-
CCCCAAGGAGTT), and probes FAM-59-TTTCCAGTGTG-
GACACTGAAGA-39-BBQ (20 nM) and YAK-59-TTTCCA-
ATGTGGACACTGAAGA-39-BBQ (24 nM, annealing and am-
plification at 57uC). Oligonucleotides for detecting the c.1710T
.A polymorphism were: 1710-forward (59CAACAACCGGCTT-
GATTTACTC), 1710-reverse (59GCTGGTGGAGGAAGAGA-
TGTCA39), and probes: FAM-59-TTGGAAGTTCTGGATA-
TAAGCAGT-39-BBQ (20 nM) and YAK-59-AATTGGAAG-
TACTGGATATAAGCAGT-BBQ (24 nM, annealing/amplifica-
tion at 60uC). For identification of the polymorphism at position
c.*1604, we used 1604-forward (59GCAGTGCCAAAGGCTT-
TACTT), 1604-reverse (59GATTAATTTGGGAATTTGTGAC-
CCT), and the LNA-probes FAM-59-TGAGTACACACTAAAT-
GAATT-39-BBQ (24 nm), YAK-59-TGTGAGTATACACTAA-
ATGAAT-39-BBQ (24 nmol, annealing/amplification at 59uC).
The c.-17C.T polymorphism was typed using 217-forward
(59ATCTCAAGCTGATCTTGGCACC), 217 reverse (59GGT-
TTCAGTTGTTTCCACAAAGATT), and LNA-probes FAM-
59TCCAAAATGGAATGTAGAGGTCTG-39-BBQ, YAK-59-T-
CCAGAATGGAATGTAGAGGTCTG-39-BBQ (20 nM each,
annealing/amplification at 60uC). Primers and probes were
designed and synthesized by TIPMolbiol, Berlin, Germany. Allele
calling was performed on the basis of the amplification and post-
amplification plate reads.
Statistical analysis
Survival analysis was performed using the LIFETEST and
LIFEREG procedures of the SAS software package (SAS version
TLR7 Variants in Rhesus Macaques
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survival curves were assessed for statistical significance using a log-
rank test with the appropriate degrees of freedom. Unbalanced
analysis of variance (ANOVA) of log-transformed viral load data
was performed using SAS procedure GLM. Kaplan-Meier
survival curves were prepared with SigmaPlot 8.0 (IBM SPPS
Inc. Somers, NY). All other statistical analyses were carried out
using the FREQ procedure of SAS.
Analysis of RNA secondary structure
Two online prediction tools were employed for RNA secondary
structure analysis, namely the Contrafold option in CentroidFold
[58] and RNAfold from the Vienna RNA Websuite [59].
Secondary structure prediction of the region encoding the signal
peptide covered nucleotide positions 1 to 78 while positions 2136
to 78 were involved in the analysis of the c.-17C.T polymor-
phism. For the remaining two polymorphisms, 30 base pairs both
upstream and downstream of the site of interest were included.
Supporting Information
Figure S1 Alignment of rhesus and human TLR7 gene
DNA sequences. The rhesus genomic DNA and refseq mRNA
(acc. no. NM_001130426) sequences were taken from the USCS
genome browser (http://genome.ucsc.edu/). Untranslated regions
are still hypothetical. Coding sequences are shown in black,
untranslated regions are given in purple. Polymorphic positions in
the rhesus sequence are marked.
(DOC)
Figure S2 Alignment of rhesus and human TLR7 amino
acid sequence. Amino acid exchanges between human and
rhesus are shown in bold, identity between deduced amino acid
residues is depicted by a dot. Signal peptide, transmembrane and
TIR domain are marked by red letters. Polymorphic sites in the
rhesus TLR7 sequence are annotated (green for synonymous, blue
for non-synonymous nucleotide exchanges).
(DOC)
Figure S3 Kaplan Meier Survival curves of SIV-infected
male rhesus macaques of Indian origin stratified by
MHC genotype. ‘MHC adjusted’ refers to the exclusion of
animals carrying either Mamu-A1*001, B*008 or an MHC
genotype known to be associated with rapid disease progression.
A: untreated SIV-infected macaques (p,0.01). B: immunized
SIV-infected macaques (p,0.01).
(TIF)
Table S1 Primers used for PCR amplification of the rhesus
macaque TLR7 gene region.
(DOC)
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